The most recent American Society of Hematology ITP clinical guidelines recommend thrombopoietin receptor agonists (TPO-RA) rather than rituximab and rituximab over splenectomy [2]. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.